BioNet’s Recombinant Pertussis Vaccine Submitted to European Medicines Agency (EMA)

Contributed by: Business Wire

Tags

Health

Other Science

General Health

Research

Science

Pharmaceutical

Biotechnology

Recombinant Pertussis Vaccine

More Like This

Moderna Announces Global Regulatory Submissions For Its Respiratory Syncytial Virus (RSV) Vaccine, MRNA-1345

UK MHRA Grants Innovation Passport Designation to ILiAD Biotechnologies BPZE1 Next Generation Intranasal Pertussis Vaccine

ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases

EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna’s Updated Covid-19 Vaccine in The European Union

Moderna Submits Regulatory Application to the European Medicines Agency for Its Updated COVID-19 Vaccine

Virometix AG Announces Positive Data from Phase 1 Trial of V-212, a Fully Synthetic, Serotype-Independent Vaccine Development Candidate for the Prevention of Pneumococcal Disease

EMA Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Marketing Authorization Of Moderna’s RSV Vaccine, mRESVIA(R)

Moderna Receives European Commission Approval for RSV Vaccine mRESVIA(R)